From the Departments of Neurosurgery (A.R.R., P.-F.D., M.R.), Neuroradiology (P.-F.D., J.C., R.I.M., P.W., A.T.), Neuroscience (A.R.R., V.F., C.V.L.T., T.A., P.T., M.W.H., R.I.M.), Neurology (K.W., U.N., M.W.H.), and Behavioral Medicine and Psychiatry (M.W.H.), Rockefeller Neuroscience Institute, Department of Medicine (S.H.), and West Virginia Clinical and Translational Science Institute (S.H.), West Virginia University, Morgantown; and the Department of Neurology, Vanderbilt University, Nashville (D.O.C.).
N Engl J Med. 2024 Jan 4;390(1):55-62. doi: 10.1056/NEJMoa2308719.
Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly aducanumab infusions to temporarily open the blood-brain barrier with the goal of enhancing amyloid removal in selected brain regions in three participants over a period of 6 months. The reduction in the level of Aβ was numerically greater in regions treated with focused ultrasound than in the homologous regions in the contralateral hemisphere that were not treated with focused ultrasound, as measured by fluorine-18 florbetaben positron-emission tomography. Cognitive tests and safety evaluations were conducted over a period of 30 to 180 days after treatment. (Funded by the Harry T. Mangurian, Jr. Foundation and the West Virginia University Rockefeller Neuroscience Institute.).
抗淀粉样蛋白抗体已被用于降低阿尔茨海默病患者大脑中的淀粉样蛋白-β（Aβ）负荷。我们在 3 名参与者中，每个参与者在 6 个月内接受 6 次每月的 aducanumab 输注，同时应用聚焦超声来短暂打开血脑屏障，目的是增强选定脑区的淀粉样蛋白清除。通过氟-18 氟比他滨正电子发射断层扫描测量，与未接受聚焦超声治疗的对侧半球同源区域相比，在接受聚焦超声治疗的区域中 Aβ 水平的降低在数值上更大。在治疗后 30 至 180 天期间进行了认知测试和安全性评估。（由 Harry T. Mangurian，Jr. 基金会和西弗吉尼亚大学洛克菲勒神经科学研究所资助）。
